Anti-CD38 Targeted Nanoparticles for Drug Delivery in Multiple Myeloma

被引：0
|
作者：
De La Puente, Pilar [1 ]
Jin, Abbey [1 ,2 ]
Luderer, Micah John [1 ]
Muz, Barbara [1 ]
King, Justin A. [3 ]
Vij, Ravi [3 ]
Azab, Abdel Kareem [1 ]
机构：
[1] Washington Univ St Louis, Sch Med, Div Canc Biol, Dept Radiat Oncol, St Louis, MO USA
[2] St Louis Coll Pharm, Dept Pharmaceut & Adm Sci, St Louis, MO USA
[3] Washington Univ, Sch Med, Div Oncol, Dept Med, St Louis, MO USA
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.2135.2135
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2135
引用
收藏
页数：5
相关论文
共 50 条
  • [31] Targeted gene delivery into human myeloma cells by an engineered anti-CD38 single chain variable fragment (scFv)-protamine complex.
    Liu, CS
    Donovan, KA
    Lust, JA
    BLOOD, 2002, 100 (11) : 210A - 211A
  • [32] Effects of Soluble and MicrovesicleBound Therapeutic Anti-CD38 Antibodies on Immune Effector Cells in Multiple Myeloma
    Faini, Angelo Corso
    Castella, Barbara
    Horenstein, Alberto
    Morandi, Fabio
    Malavasi, Fabio
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S418 - S418
  • [33] Recent Developments in Convenience of Administration of the Anti-CD38 Antibody Isatuximab: Subcutaneous Delivery and Fast Intravenous Infusion in Patients With Multiple Myeloma
    Quach, Hang
    Parmar, Gurdeep
    Mateos, Maria-Victoria
    Ailawadhi, Sikander
    Leleu, Xavier
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (06): : 358 - 363
  • [34] ANALYSIS OF THE USE OF THE ANTI-CD38 MONOCLONAL ANTIBODY IN PATIENTS WITH MULTIPLE MYELOMA FROM OUR CENTER
    Pimentel, Villar M. A.
    Anguita, Arance M. M.
    Almagro, Torres F.
    Lopez, Lopez J. A.
    HAEMATOLOGICA, 2021, 106 (10) : 337 - 337
  • [35] CLINICAL OUTCOMES ASSOCIATED WITH ANTI-CD38 RETREATMENT IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: A REVIEW OF THE LITERATURE
    McNamara, S.
    Chorazy, J.
    Pandey, A.
    Bitetti, J.
    Boytsov, N.
    Purser, M.
    Iheanacho, I.
    VALUE IN HEALTH, 2024, 27 (06) : S31 - S31
  • [36] Clinical outcomes of retreatment with daratumumab-based regimens in anti-CD38 refractory multiple myeloma
    Tan, Carlyn Rose Co
    Rueda, Colin
    Shekarkhand, Tala
    Derkach, Andriy
    Korde, Neha
    Maclachlan, Kylee
    Hultcrantz, Malin
    Hassoun, Hani
    Mailankody, Sham
    Shah, Urvi A.
    Rajeeve, Sridevi
    Lahoud, Oscar Boutros
    Shah, Gunjan L.
    Scordo, Michael
    Chung, David J.
    Landau, Heather Jolie
    Giralt, Sergio
    Usmani, Saad Zafar
    Lesokhin, Alexander M.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [37] Treatment of Multiple Myeloma in Patients Refractory to Daratumumab/Anti-CD38 Monoclonal Antibodies: A Systematic Review
    Tan, Chia Jie
    Kacerek, Dylan
    Kampirapawong, Nattawara
    Godara, Amandeep
    Chaiyakunapruk, Nathorn
    CANCER MEDICINE, 2025, 14 (05):
  • [38] Genomic and Immune Determinants of Resistance to Anti-CD38 MoAb Based Therapy in Relapsed Multiple Myeloma
    Ziccheddu, Bachisio
    Giannotta, Claudia
    D'Agostino, Mattia
    Bertuglia, Giuseppe
    Saraci, Elona
    Oliva, Stefania
    Diamond, Benjamin
    Bolli, Niccolo
    Corradini, Paolo
    Coffey, David
    Landgren, Ola
    Bruno, Benedetto
    Boccadoro, Mario
    Massaia, Massimo
    Maura, Francesco
    Larocca, Alessandra
    BLOOD, 2023, 142
  • [39] Effects of Soluble and MicrovesicleBound Therapeutic Anti-CD38 Antibodies on Immune Effector Cells in Multiple Myeloma
    Oses, Lucrecia
    Brulc, Erika
    Carretero, Marcelina
    Nucifora, Elsa
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S418 - S418
  • [40] Determinants of Response to Anti-CD38 and Bispecific Combination Therapy in Patients with Relapsed/Refractory Multiple Myeloma
    Aleman, Adolfo
    Zajdman, Ariel Kogan
    Mouhieddine, Tarek
    Upadhyaya, Bhaskar
    Van Oekelen, Oliver
    Lagana, Alessandro
    Grossman, Leah
    Thibaud, Santiago
    Sanchez, Larysa
    Richard, Shambavi
    Rossi, Adriana
    Richter, Joshua
    Cho, Hearn Jay
    Rodriguez-Valdes, Cesar
    Chari, Ajai
    Parekh, Samir
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S41 - S41
12345